Wall Street brokerages forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.52 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for United Therapeutics’ earnings. The lowest EPS estimate is $1.48 and the highest is $4.87. United Therapeutics posted earnings per share of $2.43 in the same quarter last year, which suggests a positive year-over-year growth rate of 44.9%. The company is expected to report its next quarterly earnings report on Wednesday, February 28th.

On average, analysts expect that United Therapeutics will report full-year earnings of $12.45 per share for the current year, with EPS estimates ranging from $10.39 to $13.72. For the next year, analysts anticipate that the business will post earnings of $11.62 per share, with EPS estimates ranging from $10.73 to $12.32. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $4.23 EPS.

A number of brokerages have weighed in on UTHR. TheStreet lowered United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, Cowen reiterated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $136.10.

In related news, CEO Martine A. Rothblatt sold 1,274 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares in the company, valued at approximately $271,952.01. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,258 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the transaction, the chief executive officer now owns 2,327 shares in the company, valued at $284,080.16. The disclosure for this sale can be found here. Insiders have sold a total of 22,668 shares of company stock worth $2,755,406 over the last quarter. Corporate insiders own 7.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in United Therapeutics by 3.3% in the 2nd quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after buying an additional 155,349 shares during the period. FMR LLC lifted its holdings in United Therapeutics by 2.8% in the 2nd quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock worth $551,980,000 after buying an additional 116,062 shares during the period. Vanguard Group Inc. lifted its holdings in United Therapeutics by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock worth $494,291,000 after buying an additional 25,047 shares during the period. State Street Corp lifted its holdings in United Therapeutics by 0.9% in the 2nd quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock worth $261,345,000 after buying an additional 17,179 shares during the period. Finally, Schroder Investment Management Group lifted its holdings in United Therapeutics by 42.8% in the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after buying an additional 327,360 shares during the period. Institutional investors and hedge funds own 99.94% of the company’s stock.

United Therapeutics (NASDAQ UTHR) opened at $136.21 on Monday. The firm has a market capitalization of $5,890.00, a PE ratio of 12.01 and a beta of 1.42. United Therapeutics has a one year low of $112.01 and a one year high of $169.89.

COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/united-therapeutics-co-uthr-expected-to-post-earnings-of-3-52-per-share.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.